The sharp gross margin improvement suggests better cost absorption or product mix, but operating losses persist as SG&A and R&D scale with revenue. Net margin of -35.0% in 2026Q2, though improved from -157.0% in 2025Q2, still reflects significant non-cash charges like stock-based compensation. Investors should monitor whether revenue growth can eventually outpace fixed cost growth to achieve operating leverage.

The improvement is largely due to a massive equity raise that expanded the capital base, not operational profitability. Asset turnover of 0.07x is extremely low, suggesting the $1.9B asset base, including $772.2M goodwill, is not yet generating sufficient revenue. ROE of -3.0% in 2026Q2, while improved from -17.2% in 2025Q2, still indicates that shareholder equity is not being deployed profitably.

DSO rose to 72 days and DIO to 83 days in 2026Q2, while DPO remained at 52 days, suggesting the company is tying up more cash in receivables and inventory. This may reflect acquisition integration challenges or slower collections from government customers. The lengthening CCC amplifies cash burn, as evidenced by the -38.3% FCF margin in 2026Q2.

Total debt fell to $87.1M from $333.7M in 2025Q3, and interest coverage remains negative at -48.13, but this is due to operating losses, not debt service burden. The equity raise boosted cash to $557.7M, providing a substantial buffer, but the company still relies on external funding to sustain operations. Investors should monitor whether the improved liquidity is sufficient to bridge to profitability.

The improvement is driven by the $557.7M cash balance from the equity raise, which provides a significant cushion against ongoing cash burn. However, the company's negative FCF margin of -38.3% suggests that without continued funding, liquidity could deteriorate rapidly. The high current ratio may overstate true liquidity if inventory (DIO of 83 days) becomes difficult to convert to cash.